Colinz Laboratories’ board has cleared a postal ballot to seek shareholder approval for selling or leasing its factory in Nashik and office premises in Mumbai, collectively valued at over Rs 6 crore. The company aims to monetize these assets under Section 180(1)(a) of the Companies Act through slump sale or alternate means.
Colinz Laboratories Ltd announced that its Board of Directors, at a meeting held on Tuesday, October 14, 2025, approved the issuance of a postal ballot seeking shareholder approval for the sale, lease, or disposal of key company properties — including its manufacturing facility in Nashik and office premises in Mumbai.
The company’s move is intended to streamline operations, unlock asset value, and support future strategic objectives. The postal ballot process will be conducted in compliance with the Companies Act, 2013, and SEBI Listing Regulations, with e-voting details and formal notices circulated to registered shareholders digitally.
Key Developments
-
Postal ballot initiation: The board authorized the postal ballot to approve asset disposal resolutions under Sections 180(1)(a) and 110 of the Companies Act, 2013.
-
Assets under consideration: Sale or lease of the factory located at Plot No. 60, STICE, Sinnar–Shirdi Road, Nashik, and the Mumbai office premises at A-101, A-102, and A-103, Pratik Estate, Mulund Link Road, Bhandup West.
-
Proposed valuation: The Nashik factory and Mumbai office are collectively to be sold or leased for not less than Rs 3 crore each, subject to market valuation and regulatory approval.
-
Mode of transfer: The board may execute the transfer on a slump sale basis or through any other mechanism deemed appropriate and beneficial for the company.
-
Board authorization: The board has delegated authority to finalize agreements, execute conveyance deeds, and complete all related documentation, including affixing the company seal where required.
-
Compliance and communication: Notices will be sent electronically to eligible shareholders as per records dated October 7, 2025, along with publication of statutory advertisements in English and Marathi newspapers.
This step marks a significant strategic restructuring by Colinz Laboratories, reflecting management’s intent to optimize its asset portfolio. Once approved, the move could strengthen the company’s liquidity position and create scope for reinvestment into core business operations and product innovation.
Source: Colinz Laboratories Ltd regulatory filing to BSE, Board Meeting disclosure dated October 14, 2025.